In 2023, the FDA restricted six peptides that have since drawn attention in the online wellness market: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The compounds remained unapproved, and compounding them sat in a regulatory gray area. That changed on October 28, 2026, when HHS announced it would not enforce against licensed compounding while FDA review continues.
HHS permits compounding despite CDER’s recommendation
Secretary Robert F. Kennedy Jr. signed the notice, which allows licensed US facilities to compound prescriptions for the six peptides. The decision followed an FDA advisory committee vote to recommend removing restrictions, despite contrary advice from the FDA’s Center for Drug Evaluation and Research, or CDER. BioXconomy reported the policy and HHS’s stated rationale; a separate account identifies the six compounds and the October 28 date.
CDER recommended against easing restrictions for all six, citing limited safety information, incomplete chemical characterization and contamination risks during formulation, according to Clinical Career Path’s account. BPC-157 and TB-500 are associated with claims of accelerated healing supported by preclinical animal models, not evidence of established clinical benefit, BioXconomy reported.
HHS says it wants to expand access while the FDA reviews the substances and to reduce reliance on research-use-only products sold online, including products from foreign suppliers. It says it does not intend to take enforcement action against compounding. That is an enforcement position, not a finding that the peptides are safe or effective.
Enforcement discretion changes the practical route to market
An enforcement-discretion policy describes how the government intends to apply enforcement; it does not itself confer drug approval. Under HHS’s notice, licensed compounders can proceed while FDA review continues. The compounds remain unapproved, and the notice does not supply the safety and effectiveness evidence required for an approved drug.
HHS has issued preliminary guidance on each compound’s formal identity and on testing and quality standards. Those instructions give compounders a framework for identifying and testing the substances. They do not amount to FDA premarket review. The FDA does not review these compounded peptides for safety, effectiveness or quality before marketing, according to Clinical Career Path.
The distinction matters because HHS’s stated case for the policy is comparative in practice: domestic compounding is intended to offer an alternative to research-use-only products sold online. The fact record provided here contains no comparative safety data showing that domestic compounded peptides are safer than those products. It also contains no measurements of the volume of online sales or of contamination rates among domestic compounders. Those gaps limit what can be concluded about whether the policy will make patients safer.
HHS’s access policy leaves the evidence question unresolved
The policy’s immediate effect is institutional. CDER advised against easing restrictions; HHS chose not to enforce against licensed compounding while the FDA reviews the substances. That makes access proceed alongside, rather than after, a conclusion on safety and effectiveness. The July advisory committee vote provided a competing recommendation, but the record supplied here does not establish that the committee’s vote resolved CDER’s concerns or added new safety evidence.
The policy also creates an incentive for domestic providers to meet demand that HHS says is already significant. Pharmacies can compound prescriptions under the enforcement posture HHS announced; prescribers can write them; and suppliers can seek to serve that channel. The preliminary identity and testing guidance may help define product controls, but it does not supply clinical evidence or FDA review before marketing. Those are separate questions, and the notice addresses the first more directly than the second.
The policy’s stated goal, moving patients away from online research-use-only products, is plausible as a rationale. Whether it achieves that goal, and whether domestic compounding reduces risk, cannot be answered from the available facts. No comparative safety data, domestic contamination benchmark, or precise estimate of online imports is provided in the record. Any claim that the change will produce a safer market would therefore outrun the evidence.
The larger consequence is a precedent in how the agencies handle disagreement: HHS can set an enforcement posture that allows a market to operate while FDA review remains unresolved. That does not erase CDER’s recommendation. It does reduce its immediate force as a barrier to access. Future significance will depend on whether the FDA review changes the evidence picture and whether HHS maintains the policy in light of that review.
The FDA’s review continues as HHS allows compounding
Licensed pharmacies now have an enforcement-discretion route to compound the six peptides, and HHS says the aim is to improve access while the FDA reviews them. The policy does not approve the compounds or establish safety and effectiveness. It also does not answer whether domestic supply is safer than the online products it is meant to displace.
The starting point was a 2023 FDA restriction on these six substances. In 2026, HHS allowed compounding to proceed despite CDER’s recommendation against easing those restrictions. The compounds and the unresolved evidence remain; the federal government’s enforcement posture has changed.
